BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32096175)

  • 21. LINC01116 promotes proliferation, invasion and migration of osteosarcoma cells by silencing p53 and EZH2.
    Zhang ZF; Xu HH; Hu WH; Hu TY; Wang XB
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6813-6823. PubMed ID: 31486480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long non-coding RNA GClnc1 promotes progression of colorectal cancer by inhibiting p53 signaling pathway.
    Dong YX; Pang ZG; Zhang JC; Hu JQ; Wang LY
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5705-5713. PubMed ID: 31298323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LncRNA GClnc1 may contribute to the progression of ovarian cancer by regulating p53 signaling pathway.
    Li H; Zeng Z; Yang X; Chen Y; He L; Wan T
    Eur J Histochem; 2020 Nov; 64(4):. PubMed ID: 33207861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PKMYT1 aggravates the progression of ovarian cancer by targeting SIRT3.
    Xuan ZH; Wang HP; Zhang XN; Chen ZX; Zhang HY; Gu MM
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5259-5266. PubMed ID: 32495859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lnc00908 promotes the development of ovarian cancer by regulating microRNA-495-5p.
    Jiang JN; Hong QY; Gao HJ; Lai BL; Lan JF; Yang Q
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1388-1396. PubMed ID: 30840259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA SNHG1 promotes liver cancer development through inhibiting p53 expression via binding to DNMT1.
    Li SJ; Wang L; Sun ZX; Sun SJ; Gao J; Ma RL
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2768-2776. PubMed ID: 31002127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1.
    Chen DZ; Wang TF; Dai WC; Xu X; Chen PF
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10234-10240. PubMed ID: 31841177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA TUG1 aggravates the progression of cervical cancer by binding PUM2.
    Duan W; Nian L; Qiao J; Liu NN
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8211-8218. PubMed ID: 31646551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
    Yao N; Sun JQ; Yu L; Ma L; Guo BQ
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long non-coding RNA AFAP1-AS1 promotes proliferation and migration of gastric cancer by downregulating KLF2.
    Yuan XH; Li J; Cao Y; Jie ZG; Zeng YF
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):673-680. PubMed ID: 32016968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
    Meng XF; Zhao LY; Chu XF
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LncRNA CACS15 accelerates the malignant progression of ovarian cancer through stimulating EZH2-induced inhibition of APC.
    Liu Y; Sun J; Yu J; Ge W; Xiao X; Dai S; Xiang Q
    Am J Transl Res; 2019; 11(10):6561-6568. PubMed ID: 31737207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA PVT1 aggravates the progression of glioma via downregulating UPF1.
    Lv ZH; Wang ZY; Li ZY
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8956-8963. PubMed ID: 31696483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LncRNA CDKN2BAS aggravates the progression of ovarian cancer by positively interacting with GAS6.
    Wang HM; Shen SL; Li NM; Su HF; Li WY
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):5946-5952. PubMed ID: 32572907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA LINC-PINT inhibits non-small cell lung cancer progression through sponging miR-218-5p/PDCD4.
    Zhang L; Hu J; Li J; Yang Q; Hao M; Bu L
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1595-1602. PubMed ID: 31010333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
    Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LINC00460 accelerates progression of ovarian cancer by activating transcriptional factor ZNF703.
    Wang X; Gan X; Liu C; Zhang W
    Oncol Lett; 2020 Jun; 19(6):4189-4194. PubMed ID: 32382355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
    Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244.
    Liu Y; He X; Chen Y; Cao D
    Mol Cell Biochem; 2020 Jan; 464(1-2):39-50. PubMed ID: 31691157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RBBP6 aggravates the progression of ovarian cancer by targeting PIK3R6.
    Liu YJ; Cui LL; Liu ZS; Jia RY; Ding YX; Xu LZ
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10366-10374. PubMed ID: 33155192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.